Joseph Schwartz
Stock Analyst at Leerink Partners
(3.21)
# 1,028
Out of 4,944 analysts
139
Total ratings
33.08%
Success rate
18.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KALV KalVista Pharmaceuticals | Maintains: Outperform | $18 → $20 | $12.98 | +54.08% | 6 | Jul 7, 2025 | |
| INSM Insmed | Maintains: Outperform | $100 → $115 | $127.75 | -9.98% | 4 | Jun 10, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Outperform | $4 → $12 | $6.62 | +81.41% | 4 | May 23, 2025 | |
| MAZE Maze Therapeutics | Initiates: Outperform | $28 | $13.22 | +111.80% | 1 | Feb 25, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $20 → $40 | $18.23 | +119.42% | 6 | Oct 11, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $11 → $14 | $0.47 | +2,866.10% | 2 | Sep 19, 2024 | |
| ANTX AN2 Therapeutics | Upgrades: Outperform | n/a | $1.06 | - | 3 | Jul 3, 2024 | |
| SLDB Solid Biosciences | Upgrades: Outperform | $12 | $6.17 | +94.49% | 6 | Jun 24, 2024 | |
| MREO Mereo BioPharma Group | Maintains: Outperform | $6 → $8 | $1.71 | +367.84% | 2 | Jun 20, 2024 | |
| SYBX Synlogic | Downgrades: Market Perform | $1 | $1.45 | -31.03% | 4 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $6 | $5.05 | +18.81% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $48.70 | -1.44% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $22.99 | -21.71% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $42.85 | -20.65% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $122 → $130 | $58.00 | +124.14% | 10 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $20.30 | +688.18% | 13 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $191.79 | -15.01% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $1.96 | +410.20% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $1.28 | +2,478.13% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $12 | $12.09 | -0.74% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $29.01 | +272.29% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $39 | $29.68 | +31.40% | 1 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $4 | $0.82 | +385.44% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $13.93 | +115.36% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $50 | $46.07 | +8.53% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $55.03 | -45.48% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $56 | $15.78 | +254.88% | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $7.12 | +96.77% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $2.03 | +492.59% | 2 | Sep 26, 2017 |
KalVista Pharmaceuticals
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $12.98
Upside: +54.08%
Insmed
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $127.75
Upside: -9.98%
Fulcrum Therapeutics
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $6.62
Upside: +81.41%
Maze Therapeutics
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $13.22
Upside: +111.80%
Travere Therapeutics
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $18.23
Upside: +119.42%
Applied Therapeutics
Sep 19, 2024
Maintains: Outperform
Price Target: $11 → $14
Current: $0.47
Upside: +2,866.10%
AN2 Therapeutics
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.06
Upside: -
Solid Biosciences
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $6.17
Upside: +94.49%
Mereo BioPharma Group
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $1.71
Upside: +367.84%
Synlogic
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.45
Upside: -31.03%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $5.05
Upside: +18.81%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $48.70
Upside: -1.44%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $22.99
Upside: -21.71%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $42.85
Upside: -20.65%
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $58.00
Upside: +124.14%
Jan 20, 2023
Reiterates: Outperform
Price Target: $160
Current: $20.30
Upside: +688.18%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $191.79
Upside: -15.01%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $1.96
Upside: +410.20%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $1.28
Upside: +2,478.13%
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $12.09
Upside: -0.74%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $29.01
Upside: +272.29%
May 26, 2022
Maintains: Outperform
Price Target: $36 → $39
Current: $29.68
Upside: +31.40%
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $0.82
Upside: +385.44%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $13.93
Upside: +115.36%
May 11, 2022
Maintains: Outperform
Price Target: $53 → $50
Current: $46.07
Upside: +8.53%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $55.03
Upside: -45.48%
May 3, 2022
Maintains: Outperform
Price Target: $71 → $56
Current: $15.78
Upside: +254.88%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $7.12
Upside: +96.77%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $2.03
Upside: +492.59%